United StatesStop STALLING Act
What it does
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
More detail
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- Apr 10Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.Latest
- Apr 10Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- Apr 3Committee on the Judiciary. Ordered to be reported without amendment favorably.
- Mar 24Introduced in Senate
- Mar 24Read twice and referred to the Committee on the Judiciary.Introduced